![Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data - Vedran Pavlovic, Lei Yang, Henry Lik-Yuen Chan, Jinlin Hou, Harry L Janssen, Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data - Vedran Pavlovic, Lei Yang, Henry Lik-Yuen Chan, Jinlin Hou, Harry L Janssen,](https://journals.sagepub.com/cms/10.3851/IMP3304/asset/images/large/10.3851_imp3304-fig1.jpeg)
Peginterferon Alfa-2a (40 kD) Stopping Rules in Chronic Hepatitis B: A Systematic Review and Meta-Analysis of Individual Participant Data - Vedran Pavlovic, Lei Yang, Henry Lik-Yuen Chan, Jinlin Hou, Harry L Janssen,
![JCM | Free Full-Text | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens JCM | Free Full-Text | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens](https://www.mdpi.com/jcm/jcm-12-00361/article_deploy/html/images/jcm-12-00361-g001.png)
JCM | Free Full-Text | Short-Term Peg-IFN α-2b Re-Treatment Induced a High Functional Cure Rate in Patients with HBsAg Recurrence after Stopping Peg-IFN α-Based Regimens
Pegylated Interferon α-2a Triggers NK-Cell Functionality and Specific T-Cell Responses in Patients with Chronic HBV Infection without HBsAg Seroconversion | PLOS ONE
![Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study – ScienceOpen Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study – ScienceOpen](https://www.scienceopen.com/document_file/03b6d449-f27e-41c9-861c-0cfd3626266b/PubMedCentral/large.png)
Efficacy and Safety of Pegylated Interferon alfa-2b in Moderate COVID-19: A phase II, randomized, controlled, open-label study – ScienceOpen
![Chronic treatment with peg-IFN-α reduces peripheral disease parameters... | Download Scientific Diagram Chronic treatment with peg-IFN-α reduces peripheral disease parameters... | Download Scientific Diagram](https://www.researchgate.net/publication/337301118/figure/fig5/AS:958472426385431@1605529042885/Chronic-treatment-with-peg-IFN-a-reduces-peripheral-disease-parameters-and-Jak2V617F.png)
Chronic treatment with peg-IFN-α reduces peripheral disease parameters... | Download Scientific Diagram
![Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study](https://f6publishing.blob.core.windows.net/edd7a4fb-1408-4727-b457-3ae49e0f504a/WJG-26-1525-g002.png)
Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study
![End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB - Journal of Hepatology End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB - Journal of Hepatology](https://www.journal-of-hepatology.eu/cms/asset/53c8822a-9cc1-401d-bda3-050ed9d66743/ga1.jpg)
End-of-treatment HBcrAg and HBsAb levels identify durable functional cure after Peg-IFN-based therapy in patients with CHB - Journal of Hepatology
![Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155 | Annals of Hepatology Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155 | Annals of Hepatology](https://multimedia.elsevier.es/PublicationsMultimediaV1/file//16652681/0000001800000003/v2_201906020907/S1665268119300353/v2_201906020907/en/main.assets/gr1.jpeg?xkr=ue/ImdikoIMrsJoerZ+w997EogCnBdOOD93cPFbanNeKOJqKH5+Za6P+RA5Vq9DlZXPJJ7QzhZa4jEjAuZJA+YcmJqzBlgeGCOMNj1MCJ2mgEzCkFy8qHcBpSlIVJu6HcB1UOiuXRZnkC5Z5s2uuWdrMwDjJVpuJzO0dgUszBUUe9gc5bWC1fv4FhqiNc4BoZ11X2QUA6dze76gPLwijbZPJ0yad0t1G2XrttIajzhRjDTXGDsvGvBKd+rhKLocaltLAPYgXp4OJn+D2GhrxkUk4LTaDVgU90HwJz6wTgZU=)
Pegylated interferon-α inhibits the proliferation of hepatocellular carcinoma cells by downregulating miR-155 | Annals of Hepatology
![Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | Scientific Reports Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | Scientific Reports](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fsrep11710/MediaObjects/41598_2015_Article_BFsrep11710_Fig1_HTML.jpg)
Peginterferon plus weight-based ribavirin for treatment-naïve hepatitis C virus genotype 2 patients not achieving rapid virologic response: a randomized trial | Scientific Reports
![PDF] Consensus Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B | Semantic Scholar PDF] Consensus Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/773a2ed1c92ed98831267442933ac3793394f2a7/4-Figure1-1.png)
PDF] Consensus Consensus on Pegylated Interferon Alpha in Treatment of Chronic Hepatitis B | Semantic Scholar
![Adjustment during Peg-IFN treatment for HBeAg-negative CHB patients.... | Download Scientific Diagram Adjustment during Peg-IFN treatment for HBeAg-negative CHB patients.... | Download Scientific Diagram](https://www.researchgate.net/publication/323831487/figure/fig2/AS:613882943000588@1523372507652/Adjustment-during-Peg-IFN-treatment-for-HBeAg-negative-CHB-patients-Abbreviations-CHB.png)
Adjustment during Peg-IFN treatment for HBeAg-negative CHB patients.... | Download Scientific Diagram
![EP1087778B1 - Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c - Google Patents EP1087778B1 - Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c - Google Patents](https://patentimages.storage.googleapis.com/05/ee/f9/7aba2b39530596/00080001.png)
EP1087778B1 - Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c - Google Patents
![Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study](https://f6publishing.blob.core.windows.net/edd7a4fb-1408-4727-b457-3ae49e0f504a/WJG-26-1525-g005.png)
Add-on pegylated interferon augments hepatitis B surface antigen clearance vs continuous nucleos(t)ide analog monotherapy in Chinese patients with chronic hepatitis B and hepatitis B surface antigen ≤ 1500 IU/mL: An observational study
![Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - ScienceDirect Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S1201971221002320-gr1.jpg)
Efficacy and safety of pegylated interferon alfa-2b in moderate COVID-19: A phase II, randomized, controlled, open-label study - ScienceDirect
![Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy](https://pubmiddleware.mims.com/resource/image/14E71BE6-679D-44F6-B25D-AA1500958B1C/OriginalThumbnail/THUMBNAIL_Risk%20of%20HCC%20lower%20with%20tenofovir%20than%20entecavir.jpg)
Add-on, switch-to PEG-IFN therapy strategies improve serological response in CHB patients | Latest news for Doctors, Nurses and Pharmacists | Pharmacy
![Average PEG-IFN concentration in serum. Data correspond to 15 healthy... | Download Scientific Diagram Average PEG-IFN concentration in serum. Data correspond to 15 healthy... | Download Scientific Diagram](https://www.researchgate.net/publication/49623550/figure/fig1/AS:202551212417026@1425303380250/Average-PEG-IFN-concentration-in-serum-Data-correspond-to-15-healthy-male-subjects-who.png)
Average PEG-IFN concentration in serum. Data correspond to 15 healthy... | Download Scientific Diagram
![In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a | Journal of Pharmacology and Experimental Therapeutics In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a | Journal of Pharmacology and Experimental Therapeutics](https://jpet.aspetjournals.org/content/jpet/338/3/984/F2.large.jpg)
In Vivo Pharmacology and Toxicology Evaluation of Polyethylene Glycol-Conjugated Interferon β-1a | Journal of Pharmacology and Experimental Therapeutics
![Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology Management of adverse effects of Peg-IFN and ribavirin therapy for hepatitis C | Nature Reviews Gastroenterology & Hepatology](https://media.springernature.com/lw685/springer-static/image/art%3A10.1038%2Fnrgastro.2011.21/MediaObjects/41575_2011_Article_BFnrgastro201121_Fig3_HTML.jpg)